Inhibitor-immunology-study 	Inhibitor-immunology-study 	 NNP	B-NP
.  	.  	 .	O
Evaluation  	Evaluation  	 NN	O
of  	of  	 IN	O
inhibitor  	inhibitor  	 JJ	B-NP
development  	development  	 NN	I-NP
in  	in  	 IN	O
haemophilia  	haemophilia  	 JJ	B-NP
B  	B  	 NN	I-NP
The  	The  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
inhibitors  	inhibitors  	 NN	O
in  	in  	 IN	O
haemophilia  	haemophilia  	 JJ	B-NP
B  	B  	 NNP	I-NP
is  	is  	 VBZ	O
one  	one  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
most  	most  	 RBS	O
important  	important  	 JJ	O
complications  	complications  	 NNS	B-NP
of  	of  	 IN	I-NP
replacement  	replacement  	 NN	I-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
affecting  	affecting  	 VBG	B-NP
mortality  	mortality  	 NN	I-NP
and  	and  	 CC	O
morbidity 	morbidity 	 NN	O
.  	.  	 .	O
Inhibitor  	Inhibitor  	 JJ	B-NP
development  	development  	 NN	I-NP
is  	is  	 VBZ	O
based  	based  	 VBN	O
on  	on  	 IN	O
complex  	complex  	 JJ	O
immunological  	immunological  	 JJ	B-NP
factors 	factors 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
to  	to  	 TO	O
date 	date 	 NN	O
,  	,  	 ,	O
only  	only  	 RB	O
little  	little  	 RB	O
is  	is  	 VBZ	O
known  	known  	 VBN	O
about  	about  	 IN	O
its  	its  	 PRP$	O
underlying  	underlying  	 JJ	O
mechanisms 	mechanisms 	 NNS	O
.  	.  	 .	O
Here 	Here 	 RB	O
,  	,  	 ,	O
we  	we  	 PRP	O
present  	present  	 VBP	O
first  	first  	 JJ	O
results  	results  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
haemophilia  	haemophilia  	 JJ	B-NP
B  	B  	 NN	I-NP
group  	group  	 NN	I-NP
of  	of  	 IN	O
our  	our  	 PRP$	O
Inhibitor-Immunology  	Inhibitor-Immunology  	 JJ	B-NP
study 	study 	 NN	I-NP
.  	.  	 .	O
So  	So  	 RB	O
far  	far  	 RB	O
we  	we  	 PRP	O
have  	have  	 VBP	O
analysed  	analysed  	 RB	O
15  	15  	 CD	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
haemophilia  	haemophilia  	 JJ	B-NP
B.  	B.  	 NNP	I-NP
Four  	Four  	 CD	O
of  	of  	 IN	O
them  	them  	 PRP	O
developed  	developed  	 VBD	O
a  	a  	 DT	O
high  	high  	 JJ	O
titre  	titre  	 JJ	B-NP
inhibitor 	inhibitor 	 NN	I-NP
;  	;  	 :	O
the  	the  	 DT	O
remaining  	remaining  	 JJ	O
11  	11  	 CD	O
had  	had  	 VBD	O
no  	no  	 DT	O
inhibitor 	inhibitor 	 NN	O
.  	.  	 .	O
We  	We  	 PRP	O
evaluated  	evaluated  	 VBD	O
9  	9  	 CD	O
SNPs  	SNPs  	 NN	B-NP
in  	in  	 IN	O
8  	8  	 CD	O
genes  	genes  	 NNS	O
( 	( 	 -LRB-	O
CD40 	CD40 	 NNP	B-NP
,  	,  	 ,	O
CTLA-4  	CTLA-4  	 NNP	B-NP
,  	,  	 ,	O
IL-1β 	IL-1β 	 NNP	B-NP
,  	,  	 ,	O
IL-10 	IL-10 	 NNP	B-NP
,  	,  	 ,	O
TLR2  	TLR2  	 NNP	B-NP
,  	,  	 ,	O
TLR4 	TLR4 	 NNP	B-NP
,  	,  	 ,	O
TLR9 	TLR9 	 NNP	B-NP
,  	,  	 ,	O
TNF-α 	TNF-α 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
We  	We  	 PRP	O
compared  	compared  	 VBD	O
the  	the  	 DT	O
distribution  	distribution  	 NN	B-NP
of  	of  	 IN	O
these  	these  	 DT	O
alleles  	alleles  	 NN	B-NP
between  	between  	 IN	O
inhibitor  	inhibitor  	 NN	O
and  	and  	 CC	O
non-inhibitor  	non-inhibitor  	 JJ	B-NP
haemophilia  	haemophilia  	 JJ	I-NP
B  	B  	 NN	I-NP
patients  	patients  	 NNS	I-NP
and  	and  	 CC	O
between  	between  	 IN	O
haemophilia  	haemophilia  	 JJ	B-NP
B  	B  	 NN	I-NP
patients  	patients  	 NNS	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
normal  	normal  	 JJ	B-NP
male  	male  	 JJ	I-NP
control  	control  	 NN	I-NP
population 	population 	 NN	I-NP
.  	.  	 .	O
HLA  	HLA  	 NNP	B-NP
typing  	typing  	 NN	I-NP
was  	was  	 VBD	O
performed  	performed  	 VBN	O
in  	in  	 IN	O
all  	all  	 DT	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Results 	Results 	 NNS	O
,  	,  	 ,	O
discussion 	discussion 	 NN	O
:  	:  	 :	O
There  	There  	 EX	O
appears  	appears  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
a  	a  	 DT	O
trend  	trend  	 NN	O
towards  	towards  	 IN	O
a  	a  	 DT	O
skewed  	skewed  	 JJ	O
distribution  	distribution  	 NN	B-NP
of  	of  	 IN	I-NP
TLR  	TLR  	 NNP	I-NP
9 	9 	 CD	O
,  	,  	 ,	O
IL-10  	IL-10  	 NNP	B-NP
and  	and  	 CC	O
CTLA4  	CTLA4  	 CD	B-NP
alleles  	alleles  	 NN	I-NP
in  	in  	 IN	O
haemophilia  	haemophilia  	 JJ	B-NP
B  	B  	 NN	I-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
Due  	Due  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
limited  	limited  	 JJ	O
number  	number  	 NN	O
these  	these  	 DT	O
differences  	differences  	 NNS	O
are 	are 	 VBP	O
,  	,  	 ,	O
however 	however 	 RB	O
,  	,  	 ,	O
not  	not  	 RB	O
statistically  	statistically  	 RB	O
significant 	significant 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
t-test  	t-test  	 JJ	B-NP
of  	of  	 IN	O
all  	all  	 DT	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
inhibitor  	inhibitor  	 JJ	O
versus  	versus  	 NN	O
without  	without  	 IN	O
inhibitor  	inhibitor  	 NN	O
was  	was  	 VBD	O
significant  	significant  	 JJ	O
for  	for  	 IN	O
HLA-A*03  	HLA-A*03  	 NNP	B-NP
and  	and  	 CC	O
DPB1*0401  	DPB1*0401  	 NNP	B-NP
and  	and  	 CC	O
borderline  	borderline  	 NN	O
for  	for  	 IN	O
DRB1*0201 	DRB1*0201 	 CD	B-NP
.  	.  	 .	O
